This approach, compared with conventional immunohistochemistry, validated the enhanced accuracy and prognostic significance of TOP2A expression, establishing it as an independent prognostic indicator in triple-negative breast cancer [105]. The gene discussed is TOP2A; the disease is triple-negative breast carcinoma.